ENTITY
Abbvie Inc

Abbvie Inc (ABBV US)

176
Analysis
Health Care • United States
AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.
more
bullish•S&P 500 INDEX
•12 Dec 2019 21:11

U. S. Equity Strategy: Small-Caps Closing the Gap

Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...

Logo
518 Views
Share
bullish•S&P 500 INDEX
•30 Oct 2019 04:35

U.S. Equity Strategy: Dramatic Improvement

Encouraging developments continue to pour in. Over the past week we have seen dramatic improvements that could be setting the stage for a...

Logo
469 Views
Share
bullish•Allergan Plc
•31 Aug 2019 08:47

Allergan Plc Acquisition by AbbVie Inc. – A Botox Deal with Some Wrinkles

On June 25, 2019, Abbvie Inc (ABBV US) announced its acquisition of Botox-maker Allergan Plc (AGN US) in a $63 billion cash and stock deal in which...

Logo
788 Views
Share
•21 Aug 2019 02:46

Shanghai Henlius Biotech IPO Initiation: Going Large

Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...

Logo
840 Views
Share
bearish•Celltrion Healthcare
•06 Feb 2019 11:41

Biosimilar Battlefield: The Remsima/Inflectra Warning

2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...

Share
x